Potential of CNM-Au8 Gold Nanocrystals to Treat ALS
Episode 89, May 19, 2023, 10:00 AM
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with James Berry, MD, PhD, director of the Massachusetts General Hospital ALS Care Center. At the 2023 American Academy of Neurology Annual Meeting, he spoke about new data from a study assessing CNM-Au8, a nanocrystal formulation in development for patients with ALS and other neurological diseases. Additionally, he talked about the current unmet needs in the ALS community, including the need for more diverse treatment options and increased research.
Looking for more Multiple Sclerosis discussion? Check out the NeurologyLive® neuromuscular clinical focus page.
Episode Breakdown:
In this episode, we spoke with James Berry, MD, PhD, director of the Massachusetts General Hospital ALS Care Center. At the 2023 American Academy of Neurology Annual Meeting, he spoke about new data from a study assessing CNM-Au8, a nanocrystal formulation in development for patients with ALS and other neurological diseases. Additionally, he talked about the current unmet needs in the ALS community, including the need for more diverse treatment options and increased research.
Looking for more Multiple Sclerosis discussion? Check out the NeurologyLive® neuromuscular clinical focus page.
Episode Breakdown:
- 1:15 – Clinical development program of CNM-Au8
- 3:40 – Safety findings, treatment responses of CNM-Au8
- 4:20 – Next steps in research
- 6:25 – Neurology News Minute
- 8:45 – Conducting safe trials
- 10:00 – Remaining unmet needs for patients with ALS
- 11:15 – Need for additional research
This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
FDA Approves Brexpiprazole as First Therapy for Alzheimer Agitation
FDA Panel Votes in Favor of Gene Therapy SRP-9001 for Duchenne Muscular Dystrophy in Tight Decision
Alzheimer Agent COYA 301 Halts Cognitive Decline, Restores Regulatory T Cell Dysfunction in Phase 1 Study
Phase 2 Data Highlight Fenebrutinib's Impact on Brain Lesions in Relapsing Multiple Sclerosis
Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
REFERENCES
1. Berry J, Maragakis N, Paganoni S, et al. Evidence for Survival Benefit in ALS with CNM-Au8 Treatment Across Three Study Populations. Presented at: 2023 AAN Annual Meeting; April 22-27, Boston, Massachusetts.